I welcome additional comments from our Radiology Oncologists, but it seems patients may not need axillary surgery, this eliminated adverse events such as lymphedema.
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.
Somewhat disappointing as this was a negative study, however it is still an option for patients who are not candidates for mFOLFIRINOX.
Confirms what we already know. No real surprises.
Confirms what we already know. No real surprises.
Three trial updates confirm what we already know and practice.
In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.
Confirms what we already know. No real surprises.
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
